Top Stories
Cancer & Disease Research Sponsored by Beckman Coulter
MD Anderson, Xencor partner on XmAb candidates
The University of Texas MD Anderson Cancer Center and Xencor have entered a strategic collaboration to study investigational treatments for cancers. Together, they will collaborate to design and execute clinical studies with Xencor's X monoclonal antibody (XmAb) drug candidates.
|
|
|
Kite submits BLA for CAR-T in non-Hodgkin lymphomas
Kite, a Gilead company, has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for axicabtagene ciloleucel (Yescarta) for the treatment of relapsed or refractory follicular lymphoma or marginal zone lymphomas after two or more prior therapies.
|
|
|
Protein engineering creates highly potent experimental SARS-CoV-2 vaccine
A bioengineering technique that utilizes various naturally occurring sequences and de novo design of messenger RNA (mRNA) components was applied to develop an mRNA-based vaccine that could be highly effective against SARS-CoV-2, according to a new article published in Advanced Materials on September 2.
|
|
|
|
Cell Biology
Drug Discovery & Development
Experts draw lessons from FDA's hydroxychloroquine EUA controversy
Public health and regulatory experts advocated for changes to the U.S. Food and Drug Administration (FDA) emergency use authorization (EUA) process in a viewpoint published online August 31 in the Journal of the American Medical Association. They offer a set of recommendations to improve the process going forward as more COVID-19 vaccines and treatments emerge.
|
|
|
|
Genomics Sponsored by Nvidia
New gene therapy destroys latent oral herpes in mice
Researchers recently reported that they were able to eliminate latent herpes simplex virus 1 in mice using a new gene editing technique that targets the root cause of oral herpes. The findings were published on August 18 in Nature Communications.
|
|
|
|
Immunology Sponsored by Beckman Coulter
What Your Colleagues are Buzzing About
|